Exogenous DGLA Triggers Ferroptosis via ACSL4 in AML: Mechanistic Insights and Research Applications

Study Background and Research Question

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy with persistently high morbidity and mortality. A major clinical obstacle is the development of chemotherapy resistance, frequently associated with the evasion of apoptosis by leukemia cells. Although conventional therapies predominantly induce apoptosis, alternative cell death mechanisms—such as ferroptosis—have become a focus for overcoming resistance. Ferroptosis is an iron-dependent, regulated cell death pathway driven by lipid peroxidation, distinct from apoptosis, necrosis, and autophagy. While several tumor types demonstrate sensitivity to ferroptosis, its metabolic regulation and therapeutic exploitation in AML remain insufficiently characterized. The reference study (Jiang et al., 2025) addresses this gap by investigating the role of lipid metabolic reprogramming—specifically via acyl-CoA synthetase long-chain family member 4 (ACSL4)—in regulating ferroptosis sensitivity in AML cells.

Key Innovation from the Reference Study

The principal innovation of this research lies in its discovery that exogenous dihomo-γ-linolenic acid (DGLA) can induce ferroptosis in AML cells through ACSL4-mediated metabolic reprogramming. Using a combination of high-throughput targeted metabolomics and functional genetic approaches, the authors demonstrate that ACSL4 is essential for DGLA-induced ferroptotic cell death. This mechanistic insight not only clarifies the molecular link between polyunsaturated fatty acid (PUFA) metabolism and ferroptosis in leukemia but also identifies ACSL4 as a potential therapeutic target for sensitizing AML cells to ferroptosis.

Methods and Experimental Design Insights

The study employed a multi-tiered experimental approach:

• Cell Line Selection and Authentication: Multiple AML cell lines were acquired from ATCC and authenticated by short tandem repeat (STR) analysis to ensure experimental validity.
• Metabolomics Profiling: High-throughput targeted metabolomics was performed to profile fatty acid species altered during ferroptosis induction in AML cells.
• Fatty Acid Screening: Among 12 significantly altered fatty acids, DGLA was selected for further functional assays based on its pronounced impact on ferroptosis sensitivity.
• Functional Manipulation of ACSL4: CRISPR/Cas9-mediated knockout of ACSL4 was used to test its necessity in DGLA-induced ferroptosis.
• In Vivo Validation: A DGLA-enriched diet was administered in murine models to assess leukemia progression and ferroptosis induction in vivo.

This comprehensive experimental design allowed the authors to establish causal links between exogenous DGLA, lipid metabolic reprogramming, and ferroptotic cell death in AML.

Core Findings and Why They Matter

Key findings from the study include:

• Metabolic Shifts During Ferroptosis: Targeted metabolomics revealed significant alterations in 12 fatty acids, with DGLA, arachidonic acid (AA), and docosahexaenoic acid (DHA) among those most prominently changed during ferroptosis in AML cells.
• DGLA as a Ferroptosis Inducer: Exogenous DGLA not only heightened AML cell sensitivity to ferroptosis inducers but also independently triggered ferroptosis, as evidenced by increased lipid peroxidation and cell death markers.
• ACSL4 Dependency: Genetic ablation of ACSL4 abrogated DGLA-induced ferroptosis, confirming ACSL4’s central role in channeling DGLA into pro-ferroptotic lipid metabolic pathways.
• In Vivo Relevance: Dietary DGLA significantly restricted leukemia cell growth and promoted ferroptosis in animal models, suggesting translational potential.

These findings support a model in which ACSL4 acts as a metabolic gatekeeper, linking PUFA metabolism to ferroptosis sensitivity. Therapeutically, targeting this axis may provide a means to circumvent apoptosis resistance in AML, offering a new direction for cancer research and therapeutic development (Jiang et al., 2025).

Comparison with Existing Internal Articles

Recent internal resources provide context for integrating autophagy modulation and ferroptosis mechanisms in AML research. For instance, the article "Chloroquine Diphosphate: Advanced Autophagy Modulation in AML Research" explores how autophagy modulators intersect with lipid metabolic processes and ferroptosis sensitivity. While the reference study focuses on the ACSL4-PUFA axis, internal guides such as "Chloroquine Diphosphate: Autophagy Modulator for Cancer Research" and "Chloroquine Diphosphate (SKU A8628): Reliable Autophagy M..." discuss Chloroquine Diphosphate as a potent modulator of autophagy and cell cycle arrest, with demonstrable value in chemotherapy and radiotherapy sensitization workflows. Together, these resources highlight a growing recognition of the complex interplay between autophagy, lipid metabolism, and regulated cell death pathways—each contributing to the therapeutic landscape in AML and broader cancer research.

Limitations and Transferability

Although the study presents compelling preclinical evidence, several limitations should be considered:

• Model System Constraints: Most experiments were conducted in established AML cell lines and murine models; primary patient samples and clinical data are needed to confirm translational relevance.
• Dietary Versus Pharmacological Intervention: The in vivo approach used dietary DGLA; the pharmacokinetics and delivery of DGLA or ACSL4 inhibitors in humans require further study.
• Pathway Specificity: While ACSL4 is central to DGLA-induced ferroptosis, the broader lipid metabolic network and potential compensatory pathways in different AML subtypes remain to be explored.

Nevertheless, the mechanistic clarity provided by this work offers a robust foundation for future translational and therapeutic investigations.

Protocol Parameters

• Fatty acid treatment: Exogenous DGLA was administered to AML cells in vitro; concentrations and time courses should be optimized based on cell line sensitivity and assay endpoints.
• Genetic manipulation: CRISPR/Cas9-mediated ACSL4 knockout or knockdown can be used to dissect pathway dependency in ferroptosis assays.
• In vivo dietary supplementation: DGLA-enriched diets were used in murine models to assess impact on leukemia progression and ferroptosis induction.
• Ferroptosis assay endpoints: Lipid peroxidation (e.g., BODIPY-C11 staining), cell viability, and iron accumulation are recommended for confirming ferroptotic cell death.

Research Support Resources

For researchers aiming to investigate the interplay between lipid metabolism, autophagy, and ferroptosis in AML or other cancer models, robust experimental controls and modulators are essential. Chloroquine diphosphate (SKU A8628) is widely used as an autophagy modulator and has been shown to enhance the sensitivity of cancer cells to chemotherapy and radiotherapy by promoting autophagic and apoptotic pathways. Its well-characterized mechanism—including inhibition of Toll-like receptors TLR7 and TLR9 and cell cycle regulation—makes it a valuable tool for dissecting complex cell death networks in vitro and in vivo. For precise autophagy assay calibration or when combining ferroptosis and autophagy modulation, researchers can incorporate Chloroquine diphosphate according to validated protocols and manufacturer guidance. This compound is available for research use only via APExBIO.